ARMY-1

First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory acute myeloid leukemia (ARMY-1)

Study treatment

• Intravenous infusion of MEN1112 pro/Kg body weight dose on days 1, 8, 15 of a 21-day cycle. Two induction cycles followed by a 3 week End of induction period.

Inclusion criteria

• Age  ≥ 18 years
• Diagnosis of AML
• WBC count ≤ 10 x 10⁹/L at Visit 1 (Day 1)
• ECOG score 0-2

Exclusion criteria

• Acute promyelocytic leukaemia
• Haematopoietic stem cell transplantation (HSCT) performed within 3 months prior to screening visit

Participating sites

• CHU UCL Cliniques Universitaires Saint-Luc
• ZNA
• AZ Delta